PRESS RELEASE

Total Voting Rights

Guildford, UK – 1 May 2020: In accordance with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (“DTRs”), Ergomed plc (the “Company”) announces the following information.

The Company’s issued share capital as at 30 April 2020 consisted of 48,200,790 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

ENDS

Enquiries:

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.